Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Cipher Pharmaceuticals | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

Cipher Pharmaceuticals

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Cipher Pharmaceuticals has appointed John MacInnis as vice president, portfolio development and licensing. Mr. MacInnis will be responsible for identifying and evaluating pipeline products and technologies, and pursuing strategic alliances and partnerships for the company’s drugs in targeted markets.
   
Mr. MacInnis has experience in the life sciences industry with expertise in large global pharmaceutical, private equity and portfolio management consulting. Most recently, he was vice president, business development at Kromite, a consulting firm that offers strategic support to life science companies, including technical risk assessment and benchmarking, forecasting, licensing support, portfolio and resource optimization and strategic planning. He held the position of executive vice president, business development at DRI Capital, where he was responsible for the identification and evaluation of life science royalty financing opportunities. Previously, he served as director, disease area strategy within Novartis Global Marketing (Basel), and executive director, CNS Franchise within the strategic marketing group at Johnson and Johnson.
   
“We are very pleased to welcome John to the team,” said Larry Andrews, president and chief executive officer of Cipher Pharmaceuticals. “His global new product and business development knowledge, private equity experience and complementary skill set will be highly beneficial in our pursuit of new product opportunities and additional partnerships for our current late-stage portfolio.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters